• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Tzu Chi Medical Journal >A cyclooxygenase-2 inhibitor reduces serum prostatic-specific antigen levels in men with benign prostatic hyperplasia and lower urinary tract symptoms and helps differentiate chronic inflammation from prostate cancer
【24h】

A cyclooxygenase-2 inhibitor reduces serum prostatic-specific antigen levels in men with benign prostatic hyperplasia and lower urinary tract symptoms and helps differentiate chronic inflammation from prostate cancer

机译：环氧合酶2抑制剂可降低患有良性前列腺增生和下尿路症状的男性的血清前列腺特异性抗原水平，并有助于区分慢性炎症与前列腺癌

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Emerging evidence indicates that prostatic inflammation may contribute to prostatic growth in benign prostatic hyperplasia (BPH) and neoplastic changes (prostate cancer). The Medical Therapy of Prostatic Symptoms study showed that men with inflammation had a significantly higher risk of BPH progression and acute urinary retention. Evidence also shows that a cyclooxygenase-2 (COX-2) inhibitor can increase apoptotic activity in human BPH tissue. COX-2 inhibitors in combination with alpha-adrenergic blockers may increase the effectiveness of therapy for lower urinary tract symptoms (LUTS) secondary to BPH without significant side effects. COX-2 inhibitors may decrease the serum prostatic-specific antigen level and act as a biomarker to differentiate chronic inflammation from prostate cancer in patients with LUTS suggestive of BPH who do not have a palpable prostate nodule but have a serum prostatic-specific antigen level higher than 4 ng/mL. The results might provide a simple way to initially differentiate chronic inflammation from prostatic cancer. If chronic inflammation of the prostate can be reduced by COX-2 inhibitor treatment, bothersome LUTS as well as voiding conditions might be improved.
机译：越来越多的证据表明，前列腺炎症可能会导致前列腺增生（BPH）和肿瘤改变（前列腺癌）。前列腺症状的医学治疗研究表明，患有炎症的男性患BPH进展和急性尿retention留的风险明显更高。证据还表明，环氧合酶2（COX-2）抑制剂可以增加人BPH组织的凋亡活性。 COX-2抑制剂与α-肾上腺素能受体阻滞剂联用可能会提高BPH继发的下尿路症状（LUTS）的治疗效果，而没有明显的副作用。 COX-2抑制剂可能会降低血清前列腺特异性抗原水平，并作为生物标记物区分提示前列腺增生症的LUTS患者（没有明显的前列腺结节，但血清前列腺特异性抗原水平更高），从而将慢性炎症与前列腺癌区分开来超过4 ng / mL。该结果可能提供一种简单的方法来初步区分慢性炎症与前列腺癌。如果可以通过COX-2抑制剂治疗减轻前列腺的慢性炎症，则可以改善令人讨厌的LUTS以及排尿条件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号